Newton Biocapital

DeuterOncology is a preclinical-stage biotechnology company dedicated to developing innovative cancer therapies. The company's primary focus is on a first-in-class dual MET and RAS pathway inhibitor, currently under investigation as a targeted treatment for lung cancer. This lead compound aims to enhance oncology treatment outcomes and may have broader applications when combined with standard of care and other targeted agents. By optimizing the therapeutic approach to cancer, DeuterOncology seeks to improve the effectiveness of treatment options available to medical professionals and ultimately benefit cancer patients.

Developer of pharmaceutical treatments designed to treat neurological disorders by repairing neurovascular function. The company's platform assists in restoring blood-brain barrier function in acute neurological disorders such as stroke and epilepsy, traumatic brain injury, and brain cancer, as well as neurodegenerative diseases like Alzheimer's, enabling doctors to improve patient lives in a wide range of neurological disorders.

EditForce Inc. is a biotechnology company based in Fukuoka, Japan, founded in 2015. The company specializes in genome editing alternatives and offers advanced tools for RNA molecule editing, utilizing pentatricopeptide repeat (PPR) protein engineering technologies. EditForce's innovations focus on manipulating nucleic acids, specifically DNA and RNA, to facilitate research and development in various fields, including biological research, medicine, agriculture, and bio-production. Their technology allows for precise targeting of base sequences in nucleic acids, enabling significant advancements in drug development and seed research.

DeuterOncology is a preclinical-stage biotechnology company dedicated to developing innovative cancer therapies. The company's primary focus is on a first-in-class dual MET and RAS pathway inhibitor, currently under investigation as a targeted treatment for lung cancer. This lead compound aims to enhance oncology treatment outcomes and may have broader applications when combined with standard of care and other targeted agents. By optimizing the therapeutic approach to cancer, DeuterOncology seeks to improve the effectiveness of treatment options available to medical professionals and ultimately benefit cancer patients.

Perseus Proteomics Inc. is a biotechnology company based in Tokyo, Japan, focused on drug discovery and advanced antibody technology. Founded in 2001, the company specializes in antibody discovery, engineering, and target discovery, along with functional protein expression. Its services include mouse hybridoma sequencing, recombinant protein production, and contract research support for antibody development. Perseus Proteomics is dedicated to creating innovative antibody products and new medicines to improve healthcare outcomes for patients globally.

AbolerIS Pharma is a biotechnology company based in Nantes, France, focused on developing immune-modulators for the treatment of transplant rejection, graft-versus-host disease, and autoimmune disorders. Founded in 2019, the company is dedicated to creating innovative therapies that promote immune tolerance while preserving beneficial immune responses in inflammatory and degenerative conditions. Among its key products are Anti-CD45RC, a monoclonal antibody designed to deplete effector T cells, and IL-34, a cytokine that helps induce tolerogenic macrophages and regulatory T cells. AbolerIS Pharma aims to address significant unmet medical needs through its novel therapeutic approaches.

J-Pharma Co., Ltd., founded in 2005 and based in Yokohama, Japan, specializes in the development of therapeutics and diagnostic agents for cancer treatment. The company focuses on a human-genomic approach, creating novel pharmaceuticals that target specific diseases with selective agents. J-Pharma's research emphasizes the role of cell membrane transporters, which are linked to various diseases, particularly in cancer. The company has identified significant drug transporters within the human body that can enhance the evaluation and optimization of pharmacokinetics for new drug candidates. J-Pharma's product pipeline includes anti-cancer drugs and PET diagnostic agents targeting LAT1, a transporter protein associated with cancer cell growth. Through its innovative drug development and diagnostic methods, J-Pharma aims to improve human health and welfare, particularly for the aging population in industrialized nations.

Acticor Biotech SAS is a biotechnology company based in Paris, France, focused on developing therapeutic monoclonal antibodies for acute thrombotic diseases, particularly ischemic stroke. The company's lead product, Glenzocimab, is a humanized antibody aimed at addressing the critical need for new treatment options in the acute phase of stroke. Stroke affects approximately 15 million people worldwide each year, resulting in significant mortality and disability. Current treatment options are limited, with only one recommended therapy that benefits a small percentage of patients, highlighting the urgent demand for more effective solutions. Acticor Biotech was founded in 2013 and aims to provide innovative therapies that can significantly improve outcomes for stroke patients.

EditForce Inc. is a biotechnology company based in Fukuoka, Japan, founded in 2015. The company specializes in genome editing alternatives and offers advanced tools for RNA molecule editing, utilizing pentatricopeptide repeat (PPR) protein engineering technologies. EditForce's innovations focus on manipulating nucleic acids, specifically DNA and RNA, to facilitate research and development in various fields, including biological research, medicine, agriculture, and bio-production. Their technology allows for precise targeting of base sequences in nucleic acids, enabling significant advancements in drug development and seed research.

Acticor Biotech SAS is a biotechnology company based in Paris, France, focused on developing therapeutic monoclonal antibodies for acute thrombotic diseases, particularly ischemic stroke. The company's lead product, Glenzocimab, is a humanized antibody aimed at addressing the critical need for new treatment options in the acute phase of stroke. Stroke affects approximately 15 million people worldwide each year, resulting in significant mortality and disability. Current treatment options are limited, with only one recommended therapy that benefits a small percentage of patients, highlighting the urgent demand for more effective solutions. Acticor Biotech was founded in 2013 and aims to provide innovative therapies that can significantly improve outcomes for stroke patients.

Acticor Biotech SAS is a biotechnology company based in Paris, France, focused on developing therapeutic monoclonal antibodies for acute thrombotic diseases, particularly ischemic stroke. The company's lead product, Glenzocimab, is a humanized antibody aimed at addressing the critical need for new treatment options in the acute phase of stroke. Stroke affects approximately 15 million people worldwide each year, resulting in significant mortality and disability. Current treatment options are limited, with only one recommended therapy that benefits a small percentage of patients, highlighting the urgent demand for more effective solutions. Acticor Biotech was founded in 2013 and aims to provide innovative therapies that can significantly improve outcomes for stroke patients.

Sequana Medical is a medical device company based in Zurich, Switzerland, specializing in implantable pump systems designed to manage fluid balance in the body. The company's flagship product, the alfapump, addresses ascites, the accumulation of fluid in the abdominal cavity often associated with advanced liver disease, certain cancers, and congestive heart failure. The alfapump system facilitates the automatic and continuous removal of ascites by transferring excess fluid to the bladder, where it is expelled naturally. Additionally, Sequana Medical offers the alfapump DSR, which targets sodium removal in patients experiencing volume overload due to heart failure. Founded in 2006 and with a strong presence in Germany, Sequana Medical aims to improve the quality of life for patients suffering from fluid overload conditions through innovative treatment solutions.

ChromaCure will launch a drug development program to identify potential new candidates that selectively and potently inhibit cancer targets and potentially provide novel therapy for multiple forms of cancer, either as monotherapy or in combination with immunotherapy or chemotherapy.

Synergia Medical SA, founded in 2013 and based in Mont-Saint-Guibert, Belgium, specializes in the development of innovative neurostimulation medical devices. The company is focused on creating optoelectronic neurostimulators that utilize advanced materials, optical components, biosensors, and microelectronics. In particular, Synergia Medical aims to manufacture MRI-safe, implanted devices designed for treating drug-resistant epilepsy, with potential applications in other therapeutic areas. The company has achieved ISO13485 certification within a short period and has successfully developed and marketed an OEM external neurostimulator for motorized amputee prostheses. Supported by private investors and public research grants, Synergia Medical has rapidly expanded its team to include thirteen skilled professionals dedicated to advancing neurostimulation technology.

Dim3 SA specializes in the development and marketing of clinical expert platforms and medical devices aimed at improving clinical nutrition management. The company's offerings include Scorso, an application designed for the screening and monitoring of disease-related malnutrition; Nutrow, a decision support software that optimizes clinical nutrition; and Biocorder, a mobile clinical assistant. Founded in 2013 and based in Beaufays, Belgium, Dim3 addresses the critical issue of disease-related malnutrition, which poses significant health risks and incurs substantial costs in healthcare. By providing real-time assessments of patients' nutritional status and needs through scientific algorithms, Dim3 enables healthcare professionals to make timely and effective decisions that enhance patient outcomes while reducing overall healthcare expenses.